PT - JOURNAL ARTICLE AU - Raymond A. Harvey AU - Jeremy A. Rassen AU - Carly A. Kabelac AU - Wendy Turenne AU - Sandy Leonard AU - Reyna Klesh AU - William A. Meyer III AU - Harvey W. Kaufman AU - Steve Anderson AU - Oren Cohen AU - Valentina I. Petkov AU - Kathy A. Cronin AU - Alison L. Van Dyke AU - Douglas R. Lowy AU - Norman E. Sharpless AU - Lynne T. Penberthy TI - Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection AID - 10.1101/2020.12.18.20248336 DP - 2020 Jan 01 TA - medRxiv PG - 2020.12.18.20248336 4099 - http://medrxiv.org/content/early/2020/12/20/2020.12.18.20248336.short 4100 - http://medrxiv.org/content/early/2020/12/20/2020.12.18.20248336.full AB - Importance There is limited evidence regarding whether the presence of serum antibodies to SARS-CoV-2 is associated with a decreased risk of future infection. Understanding susceptibility to infection and the role of immune memory is important for identifying at-risk populations and could have implications for vaccine deployment.Objective The purpose of this study was to evaluate subsequent evidence of SARS-CoV-2 infection based on diagnostic nucleic acid amplification test (NAAT) among individuals who are antibody-positive compared with those who are antibody-negative, using real-world data.Design This was an observational descriptive cohort study.Participants The study utilized a national sample to create cohorts from a de-identified dataset composed of commercial laboratory test results, open and closed medical and pharmacy claims, electronic health records, hospital billing (chargemaster) data, and payer enrollment files from the United States. Patients were indexed as antibody-positive or antibody-negative according to their first SARS-CoV-2 antibody test recorded in the database. Patients with more than 1 antibody test on the index date where results were discordant were excluded.Main Outcomes/Measures Primary endpoints were index antibody test results and post-index diagnostic NAAT results, with infection defined as a positive diagnostic test post-index, as measured in 30-day intervals (0-30, 31-60, 61-90, >90 days). Additional measures included demographic, geographic, and clinical characteristics at the time of the index antibody test, such as recorded signs and symptoms or prior evidence of COVID-19 (diagnoses or NAAT+) and recorded comorbidities.Results We included 3,257,478 unique patients with an index antibody test. Of these, 2,876,773 (88.3%) had a negative index antibody result, 378,606 (11.6%) had a positive index antibody result, and 2,099 (0.1%) had an inconclusive index antibody result. Patients with a negative antibody test were somewhat older at index than those with a positive result (mean of 48 versus 44 years). A fraction (18.4%) of individuals who were initially seropositive converted to seronegative over the follow up period. During the follow-up periods, the ratio (CI) of positive NAAT results among individuals who had a positive antibody test at index versus those with a negative antibody test at index was 2.85 (2.73 - 2.97) at 0-30 days, 0.67 (0.6 - 0.74) at 31-60 days, 0.29 (0.24 - 0.35) at 61-90 days), and 0.10 (0.05 - 0.19) at >90 days.Conclusions Patients who display positive antibody tests are initially more likely to have a positive NAAT, consistent with prolonged RNA shedding, but over time become markedly less likely to have a positive NAAT. This result suggests seropositivity using commercially available assays is associated with protection from infection. The duration of protection is unknown and may wane over time; this parameter will need to be addressed in a study with extended duration of follow up.Question Can real-world data be used to evaluate the comparative risk of SARS-CoV-2 infection for individuals who are antibody-positive versus antibody-negative?Finding Of patients indexed on a positive antibody test, 10 of 3,226 with a NAAT (0.3%) had evidence of a positive NAAT > 90 days after index, compared with 491 of 16,157 (3.0%) indexed on a negative antibody test.Meaning Individuals who are seropositive for SARS-CoV-2 based on commercial assays may be at decreased future risk of SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunded by the National Cancer InstituteAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved under exemption by the New England Institutional Review Board (#1-9757-1). Exemption status was approved under the following category: Research involving the collection or study of existing data, documents, records, pathological specimens, or diagnostic specimens, if the investigator records the information in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects. We were granted a waiver for consent. Consent was not obtained because the study was conducted using existing de-identified administrative claims data and/or electronic health records. No human subjects were recruited for this study. Subjects were not identified directly or through identifiers linked to the subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is not publicly available.